HOME >> BIOLOGY >> NEWS
Obesity gets you where you live, UH study finds

HOUSTON, Nov. 29, 2004--Obesity is likely to affect individuals in low-income areas where fresh fruits and vegetables may not be as plentiful, according to a new University of Houston study.

The finding is suggested in a study on the availability and quality of produce in high-income versus low-income urban neighborhoods. The study was made possible by a two year, $110,000 grant from the American Heart Association Heartland Affiliate.

"Obesity disproportionately burdens low-income, ethnic minority populations," said Rebecca E. Lee, assistant professor of health and human performance and lead researcher on the study. "The results suggest that these populations have less access to healthy foods."

The study found that people living in low-income, urban neighborhoods had access to at least one convenience store and a liquor store that sold convenience foods, but very few supermarkets or grocery stores. The produce that was available to these neighborhoods included few fresh fruits and hardly any vegetables. In contrast, the high-income urban neighborhoods studied were more likely to have access to supermarkets and grocery stores and the quality and quantity of produce available was higher than those found in low-income neighborhoods.

The study was presented in a Las Vegas conference for the North American Association for the Study of Obesity and the American Diabetes Association.

Lee's research incorporates environmental and individual determinants of physical activity, dietary habits and obesity prevention in ethnic minority and underserved populations. Her work combines theory and techniques drawn from behavioral medicine, community psychology, geography, policy science, social ecology and social marketing.


'"/>

Contact: Marisa Ramirez
mrcannon@uh.edu
713-743-8152
University of Houston
2-Dec-2004


Page: 1

Related biology news :

1. Obesity found to be a risk factor for multiple myeloma
2. Obesity crisis in insects? Not a problem, says expert
3. Obesity before pregnancy linked to childhood weight problems
4. High-intensity ultrasound may launch attack on cancer, wherever it lurks
5. Waters off Washington state only second place in world where glass sponge reefs found
6. Fruit fly gene from out of nowhere is discovered
7. Where did we come from, and how did we get to where we live today?
8. Why do oysters choose to live where they could be eaten?
9. Unraveling where chimp and human brains diverge
10. Plant studies reveal how, where seeds store iron
11. Unique imaging uncovers the invisible world where surfaces meet

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Obesity gets you where you live study finds

(Date:12/11/2014)... DUBLIN , Dec. 09, 2014 Research ... http://photos.prnewswire.com/prnh/20130307/600769 ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) ... Market in India 2015-2019" report to their ... in this market is the adoption of multimodal ... one characteristic of an individual for verification and ...
(Date:12/11/2014)... Minn. , Dec. 10, 2014  Data ... physiologic monitoring, has released a new series of ... of preclinical toxicology researchers. M series, part of ... toxicologists collect the best possible physiologic data when ... Adding functional endpoints to toxicology studies has ...
(Date:12/10/2014)... 2014  Valencell, a leader in performance biometric data ... demand from its licensees for highly accurate, clinically validated ... solely coming from fitness and health sectors, but first ... wearable is only as useful as the biometric data ... driver in long-term mass consumer adoption of wearable products," ...
Breaking Biology News(10 mins):Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2New telemetry implants expected to change how large animal toxicology studies are conducted 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2
(Date:12/19/2014)... 2014 LayerBio is an MIT spin-off ... care. The National Eye Institute (NEI) at the National ... I SBIR grant to develop a drug-eluting intraocular lens ... common cause of vision loss in people over age ... to Dr. Ken Mandell, LayerBio’s Founder and CEO, "There ...
(Date:12/19/2014)... The empty capsules market is ... population and technological innovations in the empty capsules ... catalysing the growth of the empty capsules market. ... , Scope of Report , The report will ... entrants/smaller firms to gauge the pulse of the ...
(Date:12/19/2014)... YORK , Dec. 18, 2014 Relmada ... therapies for the treatment of chronic pain, announced the ... today. "This was a transformational year in ... promising future for our company," said Sergio Traversa ... year, we have executed on key financial, human resource ...
(Date:12/17/2014)... Ipsen Biopharmaceuticals, Inc., an affiliate ... IPSEY), today announced that Somatuline® Depot® (lanreotide) ... approved by the U.S. Food and Drug Administration ... (GEP-NETs) in adult patients with unresectable, well or ... improve progression-free survival (PFS). , “The approval of ...
Breaking Biology Technology:LayerBio Awarded NIH Grant to Develop a Drug Delivery Device for Cataract Surgery 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 3Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 4Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8
Cached News: